The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation

Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand's Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 3; p. e0150499
Main Authors Posuwan, Nawarat, Wanlapakorn, Nasamon, Sa-nguanmoo, Pattaratida, Wasitthankasem, Rujipat, Vichaiwattana, Preeyaporn, Klinfueng, Sirapa, Vuthitanachot, Viboonsak, Sae-lao, Siriporn, Foonoi, Monthana, Fakthongyoo, Apinya, Makaroon, Jamorn, Srisingh, Klaita, Asawarachun, Duangporn, Owatanapanich, Somchai, Wutthiratkowit, Norra, Tohtubtiang, Kraisorn, Yoocharoen, Pornsak, Vongpunsawad, Sompong, Poovorawan, Yong
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 03.03.2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1932-6203
1932-6203
DOI10.1371/journal.pone.0150499

Cover

Loading…
Abstract Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand's Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5-6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5-10, 11-20, 21-30, 31-40, 41-50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% (p<0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease.
AbstractList Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand's Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5-6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5-10, 11-20, 21-30, 31-40, 41-50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% (p<0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease.
Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand’s Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5–6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5–10, 11–20, 21–30, 31–40, 41–50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% ( p <0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease.
Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand's Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5-6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5-10, 11-20, 21-30, 31-40, 41-50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% (p<0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease.Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand's Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5-6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5-10, 11-20, 21-30, 31-40, 41-50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% (p<0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease.
Audience Academic
Author Makaroon, Jamorn
Posuwan, Nawarat
Yoocharoen, Pornsak
Poovorawan, Yong
Sae-lao, Siriporn
Sa-nguanmoo, Pattaratida
Wasitthankasem, Rujipat
Vuthitanachot, Viboonsak
Fakthongyoo, Apinya
Owatanapanich, Somchai
Vichaiwattana, Preeyaporn
Wanlapakorn, Nasamon
Tohtubtiang, Kraisorn
Vongpunsawad, Sompong
Klinfueng, Sirapa
Asawarachun, Duangporn
Srisingh, Klaita
Wutthiratkowit, Norra
Foonoi, Monthana
AuthorAffiliation 9 Trang Hospital, Mueang, Trang, Thailand
4 Lablae Hospital, Lablae, Uttaradit, Thailand
5 Naresuan University Hospital, Mueang, Phitsanulok, Thailand
Public Health England, UNITED KINGDOM
1 Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand
8 Narathiwat Ratchanakarin Hospital, Mueang, Narathiwat, Thailand
2 Chumphae Hospital, Chumphae, Khon Kaen, Thailand
6 Phra Nakhon Si Ayutthaya Hospital, Phra Nakhon Si Ayutthaya, Thailand
7 King Narai Hospital, Mueang, Lop Buri, Thailand
10 Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health, Mueang, Nonthaburi, Thailand
3 Uttaradit Hospital, Mueang, Uttaradit, Thailand
AuthorAffiliation_xml – name: 4 Lablae Hospital, Lablae, Uttaradit, Thailand
– name: 2 Chumphae Hospital, Chumphae, Khon Kaen, Thailand
– name: Public Health England, UNITED KINGDOM
– name: 3 Uttaradit Hospital, Mueang, Uttaradit, Thailand
– name: 6 Phra Nakhon Si Ayutthaya Hospital, Phra Nakhon Si Ayutthaya, Thailand
– name: 10 Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health, Mueang, Nonthaburi, Thailand
– name: 9 Trang Hospital, Mueang, Trang, Thailand
– name: 7 King Narai Hospital, Mueang, Lop Buri, Thailand
– name: 5 Naresuan University Hospital, Mueang, Phitsanulok, Thailand
– name: 1 Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand
– name: 8 Narathiwat Ratchanakarin Hospital, Mueang, Narathiwat, Thailand
Author_xml – sequence: 1
  givenname: Nawarat
  surname: Posuwan
  fullname: Posuwan, Nawarat
– sequence: 2
  givenname: Nasamon
  surname: Wanlapakorn
  fullname: Wanlapakorn, Nasamon
– sequence: 3
  givenname: Pattaratida
  surname: Sa-nguanmoo
  fullname: Sa-nguanmoo, Pattaratida
– sequence: 4
  givenname: Rujipat
  surname: Wasitthankasem
  fullname: Wasitthankasem, Rujipat
– sequence: 5
  givenname: Preeyaporn
  surname: Vichaiwattana
  fullname: Vichaiwattana, Preeyaporn
– sequence: 6
  givenname: Sirapa
  surname: Klinfueng
  fullname: Klinfueng, Sirapa
– sequence: 7
  givenname: Viboonsak
  surname: Vuthitanachot
  fullname: Vuthitanachot, Viboonsak
– sequence: 8
  givenname: Siriporn
  surname: Sae-lao
  fullname: Sae-lao, Siriporn
– sequence: 9
  givenname: Monthana
  surname: Foonoi
  fullname: Foonoi, Monthana
– sequence: 10
  givenname: Apinya
  surname: Fakthongyoo
  fullname: Fakthongyoo, Apinya
– sequence: 11
  givenname: Jamorn
  surname: Makaroon
  fullname: Makaroon, Jamorn
– sequence: 12
  givenname: Klaita
  surname: Srisingh
  fullname: Srisingh, Klaita
– sequence: 13
  givenname: Duangporn
  surname: Asawarachun
  fullname: Asawarachun, Duangporn
– sequence: 14
  givenname: Somchai
  surname: Owatanapanich
  fullname: Owatanapanich, Somchai
– sequence: 15
  givenname: Norra
  surname: Wutthiratkowit
  fullname: Wutthiratkowit, Norra
– sequence: 16
  givenname: Kraisorn
  surname: Tohtubtiang
  fullname: Tohtubtiang, Kraisorn
– sequence: 17
  givenname: Pornsak
  surname: Yoocharoen
  fullname: Yoocharoen, Pornsak
– sequence: 18
  givenname: Sompong
  surname: Vongpunsawad
  fullname: Vongpunsawad, Sompong
– sequence: 19
  givenname: Yong
  surname: Poovorawan
  fullname: Poovorawan, Yong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26938736$$D View this record in MEDLINE/PubMed
BookMark eNqNk91u0zAUxyM0xD7gDRBYQkJw0eKPxHZ2gTSmwSpNWsU6JK4s13FaV05c7GQaXPEavB5PgrOmqJkmhHKR5OT3__uck3MOk73a1TpJniM4RoShdyvX-lra8TqGxxBlMM3zR8kBygkeUQzJ3s7zfnIYwgrCjHBKnyT7mOaEM0IPktvZUoOrVikdAnAlkOC6NjfaB2nBuV7LxjQmgA9gUlVtbX7Ed1eDqXcLLysgA5hK33S62VIaK-vi989fAZxNJ0CWjfYAY_BVSx9iOFqsra503dyZPE0el9IG_ay_HyXXH89mp-eji8tPk9OTi5FiGW9GmSwIxLjAMJM0gyjlBUOQlyjLck4VnzONaM4ZLRDBUGHGsoxoxPMCU8YIIUfJy43v2rog-qYFgRiLthQzFInJhiicXIm1N5X034WTRtwFnF-IWKRRVgtMYJ4WXBV8TtOS5lJSBXVZZlDBEmIavd73p7XzShcqVuulHZgOv9RmKRbuRqQsZp6yaPCmN_DuW6tDIyoTlLaxt9q1m7zjn4Npl_ere-jD1fXUQsYCTF26eK7qTMVJyhDiCOdppMYPUPEqdGVUnLDSxPhA8HYgiEyjb5uFbEMQk6vP_89efhmyr3fYpZa2WQZn225kwhB8sdvpvy3ejnYEjjeA8i4Er0uhzGb0YmnGCgRFt0fbpoluj0S_R1Gc3hNv_f8p-wM-1SBF
CitedBy_id crossref_primary_10_1016_j_vaccine_2021_09_061
crossref_primary_10_1371_journal_pone_0225606
crossref_primary_10_1371_journal_pone_0270458
crossref_primary_10_1016_j_ekir_2024_01_014
crossref_primary_10_1186_s12876_019_0935_y
crossref_primary_10_3390_ijerph19159551
crossref_primary_10_1186_s12879_020_05221_1
crossref_primary_10_1016_j_vaccine_2019_12_065
crossref_primary_10_1186_s40794_016_0031_z
crossref_primary_10_3390_vaccines10010092
crossref_primary_10_1056_NEJMoa1708131
crossref_primary_10_1111_apt_16197
crossref_primary_10_1016_j_vaccine_2022_03_049
crossref_primary_10_1097_MD_0000000000028308
crossref_primary_10_1016_j_jceh_2019_02_007
crossref_primary_10_1093_ofid_ofz518
crossref_primary_10_1186_s12879_019_3747_3
crossref_primary_10_1371_journal_pone_0180560
crossref_primary_10_1038_nri_2017_140
crossref_primary_10_1097_INF_0000000000003730
crossref_primary_10_3390_vaccines10020267
crossref_primary_10_5812_hepatmon_128166
crossref_primary_10_1016_j_vaccine_2023_05_014
crossref_primary_10_1186_s12889_021_12429_6
crossref_primary_10_7717_peerj_7492
crossref_primary_10_1111_liv_14479
crossref_primary_10_15585_mmwr_mm6930a2
crossref_primary_10_1111_ctr_14024
crossref_primary_10_1159_000503447
crossref_primary_10_1016_j_vaccine_2017_11_027
crossref_primary_10_1038_s41598_024_57584_z
crossref_primary_10_1016_j_jve_2020_100003
crossref_primary_10_3390_vaccines9040374
crossref_primary_10_1097_MPG_0000000000002483
crossref_primary_10_1016_j_ijid_2022_09_003
crossref_primary_10_7189_jogh_07_020405
crossref_primary_10_11604_pamj_2024_47_169_40369
crossref_primary_10_1080_21645515_2025_2480403
crossref_primary_10_1111_liv_13875
crossref_primary_10_1016_j_canlet_2022_215652
crossref_primary_10_1136_bmjopen_2022_067275
crossref_primary_10_1016_j_vaccine_2017_05_047
crossref_primary_10_1371_journal_pone_0177022
crossref_primary_10_1186_s12879_025_10539_9
crossref_primary_10_1016_j_cegh_2023_101271
crossref_primary_10_1038_s41541_021_00412_6
crossref_primary_10_1016_j_jvacx_2024_100561
crossref_primary_10_1016_j_canep_2020_101765
crossref_primary_10_3390_v16020314
crossref_primary_10_3390_tropicalmed7050070
crossref_primary_10_1038_s41598_024_84854_7
crossref_primary_10_2139_ssrn_4153439
crossref_primary_10_1371_journal_pone_0202637
crossref_primary_10_5812_ircmj_15107
crossref_primary_10_1007_s40620_019_00668_1
crossref_primary_10_1016_j_jve_2023_100356
crossref_primary_10_1097_MD_0000000000006554
crossref_primary_10_1016_j_jve_2024_100577
crossref_primary_10_3389_fimmu_2019_02385
crossref_primary_10_3390_cancers9080108
crossref_primary_10_3389_fonc_2022_891652
crossref_primary_10_1038_s41575_018_0055_0
crossref_primary_10_1002_hsr2_773
crossref_primary_10_7759_cureus_18430
crossref_primary_10_3390_ijerph20054142
crossref_primary_10_1186_s12939_022_01802_5
crossref_primary_10_3390_vaccines12070710
crossref_primary_10_5223_pghn_2020_23_6_539
crossref_primary_10_1038_s41598_023_49819_2
Cites_doi 10.1016/j.vaccine.2009.08.034
10.1016/S0264-410X(00)00216-4
10.1046/j.1440-1746.2000.02096.x
10.1016/S0264-410X(99)00456-9
10.1093/clinids/20.4.992
10.1016/S0140-6736(99)07239-6
10.1016/S0264-410X(02)00461-9
10.1371/journal.pmed.1001774
10.1002/jmv.23260
10.1016/j.jhep.2013.02.015
10.1542/peds.2013-2940
10.1086/599331
10.1016/j.vaccine.2009.10.074
10.1128/CDLI.12.12.1442-1447.2005
10.1111/j.1365-3156.2006.01709.x
10.1016/j.patbio.2009.11.002
10.1620/tjem.193.197
10.4161/hv.24844
10.1093/ofid/ofv122
10.7150/ijms.2.50
10.1111/j.1365-2893.2010.01312.x
10.1002/hep.510290349
10.4161/hv.19989
ContentType Journal Article
Copyright COPYRIGHT 2016 Public Library of Science
2016 Posuwan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2016 Posuwan et al 2016 Posuwan et al
Copyright_xml – notice: COPYRIGHT 2016 Public Library of Science
– notice: 2016 Posuwan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2016 Posuwan et al 2016 Posuwan et al
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0150499
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
Biological Sciences
Agriculture Science Database
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection (ProQuest)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList




MEDLINE
MEDLINE - Academic
Agricultural Science Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Medicine
DocumentTitleAlternate HBV in Thailand after 22 Years of EPI Program
EISSN 1932-6203
ExternalDocumentID 1770226271
oai_doaj_org_article_23094d8cd8b64f69aa6c0eff50c0f026
PMC4777547
3970747921
A471181294
26938736
10_1371_journal_pone_0150499
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Thailand
Africa
Bangkok Thailand
GeographicLocations_xml – name: Thailand
– name: Africa
– name: Bangkok Thailand
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
PV9
PYCSY
RNS
RPM
RZL
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
PJZUB
PPXIY
PQGLB
RIG
BBORY
PMFND
3V.
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PKEHL
PQEST
PQUKI
RC3
7X8
5PM
PUEGO
AAPBV
ABPTK
N95
ID FETCH-LOGICAL-c758t-5ad3022d205a650148d7108f155986c8b7e169876d1320c277553e189d2677333
IEDL.DBID M48
ISSN 1932-6203
IngestDate Sun Feb 05 03:13:47 EST 2023
Wed Aug 27 01:11:43 EDT 2025
Thu Aug 21 13:48:56 EDT 2025
Fri Jul 11 10:40:32 EDT 2025
Fri Jul 25 11:35:30 EDT 2025
Tue Jun 17 21:05:33 EDT 2025
Tue Jun 10 20:32:48 EDT 2025
Fri Jun 27 04:59:02 EDT 2025
Fri Jun 27 03:45:48 EDT 2025
Thu May 22 21:11:28 EDT 2025
Mon Jul 21 05:48:42 EDT 2025
Tue Jul 01 02:09:48 EDT 2025
Thu Apr 24 23:06:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c758t-5ad3022d205a650148d7108f155986c8b7e169876d1320c277553e189d2677333
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: NP YP. Performed the experiments: NP PV SK RW PS PY. Analyzed the data: NP YP. Contributed reagents/materials/analysis tools: VV SS MF AF JM KS DA SO N. Wutthiratkowit KT. Wrote the paper: NP N. Wanlapakorn SV YP.
OpenAccessLink https://www.proquest.com/docview/1770226271?pq-origsite=%requestingapplication%
PMID 26938736
PQID 1770226271
PQPubID 1436336
PageCount e0150499
ParticipantIDs plos_journals_1770226271
doaj_primary_oai_doaj_org_article_23094d8cd8b64f69aa6c0eff50c0f026
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4777547
proquest_miscellaneous_1770873041
proquest_journals_1770226271
gale_infotracmisc_A471181294
gale_infotracacademiconefile_A471181294
gale_incontextgauss_ISR_A471181294
gale_incontextgauss_IOV_A471181294
gale_healthsolutions_A471181294
pubmed_primary_26938736
crossref_citationtrail_10_1371_journal_pone_0150499
crossref_primary_10_1371_journal_pone_0150499
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-03-03
PublicationDateYYYYMMDD 2016-03-03
PublicationDate_xml – month: 03
  year: 2016
  text: 2016-03-03
  day: 03
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2016
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References N Chimparlee (ref13) 2011; 42
A Theamboonlers (ref14) 2001; 193
F André (ref10) 2000; 18
ref1
CW Wang (ref18) 2005; 12
Y Poovorawan (ref22) 2011; 18
J Hou (ref2) 2005; 2
Y Poovorawan (ref11) 2013; 9
Y Poovorawan (ref7) 2000; 19
P Sa-Nguanmoo (ref15) 2012; 84
(ref25) 2000; 355
MH Chang (ref4) 2000; 15
WH Wen (ref5) 2013; 59
A Cheng (ref6) 2015; 2
P Yimnoi (ref16) 2015
C Qu (ref27) 2014; 11
Y Poovorawan (ref21) 2010; 28
Y Poovorawan (ref23) 2012; 8
YH Ni (ref26) 2010; 58
P Tharmaphornpilas (ref9) 2009; 27
Y Poovorawan (ref24) 2013; 9
V Chongsrisawat (ref12) 2006; 11
Y Poovorawan (ref20) 2009; 200
AB Middleman (ref17) 2014; 133
KC Hyams (ref3) 1995; 20
S Chunsuttiwat (ref8) 2002; 21
LM Huang (ref19) 1999; 29
10683538 - Vaccine. 2000 Feb 18;18 Suppl 1:S20-2
25549238 - PLoS Med. 2014 Dec;11(12):e1001774
15968340 - Int J Med Sci. 2005;2(1):50-57
11115720 - Vaccine. 2000 Nov 22;19(7-8):943-9
26566533 - Open Forum Infect Dis. 2015 Sep 01;2(4):ofv122
7795104 - Clin Infect Dis. 1995 Apr;20(4):992-1000
19892043 - Vaccine. 2010 Jan 8;28(3):730-6
22711345 - J Med Virol. 2012 Aug;84(8):1177-85
12450693 - Vaccine. 2002 Dec 13;21(3-4):188-93
20116181 - Pathol Biol (Paris). 2010 Aug;58(4):296-300
23485519 - J Hepatol. 2013 Jul;59(1):24-30
16339069 - Clin Diagn Lab Immunol. 2005 Dec;12(12):1442-7
10683019 - Lancet. 2000 Feb 12;355(9203):561-5
21706939 - Southeast Asian J Trop Med Public Health. 2011 May;42(3):609-15
11315767 - Tohoku J Exp Med. 2001 Mar;193(3):197-205
22777097 - Hum Vaccin Immunother. 2012 Jul;8(7):896-904
23732904 - Hum Vaccin Immunother. 2013 Aug;9(8):1679-84
19716459 - Vaccine. 2009 Oct 19;27(44):6110-5
26331587 - J Med Virol. 2016 Apr;88(4):664-73
24843060 - Pediatrics. 2014 Jun;133(6):e1500-7
19473096 - J Infect Dis. 2009 Jul 1;200(1):33-8
10051503 - Hepatology. 1999 Mar;29(3):954-9
20384962 - J Viral Hepat. 2011 May;18(5):369-75
17002723 - Trop Med Int Health. 2006 Oct;11(10):1496-502
10921376 - J Gastroenterol Hepatol. 2000 May;15 Suppl:E16-9
References_xml – volume: 27
  start-page: 6110
  issue: 44
  year: 2009
  ident: ref9
  article-title: Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.08.034
– volume: 19
  start-page: 943
  issue: 7–8
  year: 2000
  ident: ref7
  article-title: Impact of hepatitis B immunisation as part of the EPI
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(00)00216-4
– ident: ref1
– volume: 15
  year: 2000
  ident: ref4
  article-title: Natural history of hepatitis B virus infection in children
  publication-title: J Gastroenterol Hepatol
  doi: 10.1046/j.1440-1746.2000.02096.x
– volume: 18
  start-page: S20
  issue: Suppl 1
  year: 2000
  ident: ref10
  article-title: Hepatitis B epidemiology in Asia, the Middle East and Africa
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(99)00456-9
– volume: 20
  start-page: 992
  issue: 4
  year: 1995
  ident: ref3
  article-title: Risks of chronicity following acute hepatitis B virus infection: a review
  publication-title: Clin Infect Dis
  doi: 10.1093/clinids/20.4.992
– volume: 355
  start-page: 561
  issue: 9203
  year: 2000
  ident: ref25
  article-title: Are booster immunisations needed for lifelong hepatitis B immunity?
  publication-title: Lancet
  doi: 10.1016/S0140-6736(99)07239-6
– volume: 21
  start-page: 188
  issue: 3–4
  year: 2002
  ident: ref8
  article-title: Comparative evaluation of a combined DTP-HB vaccine in the EPI in Chiangrai Province, Thailand
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(02)00461-9
– volume: 11
  start-page: e1001774
  issue: 12
  year: 2014
  ident: ref27
  article-title: Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1001774
– volume: 84
  start-page: 1177
  issue: 8
  year: 2012
  ident: ref15
  article-title: Molecular analysis of hepatitis B virus associated with vaccine failure in infants and mothers: a case-control study in Thailand
  publication-title: J Med Virol
  doi: 10.1002/jmv.23260
– volume: 59
  start-page: 24
  issue: 1
  year: 2013
  ident: ref5
  article-title: Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2013.02.015
– year: 2015
  ident: ref16
  article-title: A molecular epidemiological study of the hepatitis B virus in Thailand after 22 years of universal immunization
  publication-title: J Med Virol
– volume: 133
  start-page: e1500
  issue: 6
  year: 2014
  ident: ref17
  article-title: Duration of protection after infant hepatitis B vaccination series
  publication-title: Pediatrics
  doi: 10.1542/peds.2013-2940
– volume: 200
  start-page: 33
  issue: 1
  year: 2009
  ident: ref20
  article-title: Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers
  publication-title: J Infect Dis
  doi: 10.1086/599331
– volume: 28
  start-page: 730
  issue: 3
  year: 2010
  ident: ref21
  article-title: Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.10.074
– volume: 12
  start-page: 1442
  issue: 12
  year: 2005
  ident: ref18
  article-title: Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay
  publication-title: Clin Diagn Lab Immunol
  doi: 10.1128/CDLI.12.12.1442-1447.2005
– volume: 11
  start-page: 1496
  issue: 10
  year: 2006
  ident: ref12
  article-title: Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization
  publication-title: Trop Med Int Health
  doi: 10.1111/j.1365-3156.2006.01709.x
– volume: 58
  start-page: 296
  issue: 4
  year: 2010
  ident: ref26
  article-title: Hepatitis B vaccination in children: the Taiwan experience
  publication-title: Pathol Biol (Paris)
  doi: 10.1016/j.patbio.2009.11.002
– volume: 193
  start-page: 197
  issue: 3
  year: 2001
  ident: ref14
  article-title: Variants within the "a" determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand's Expanded Program on Immunization (EPI)
  publication-title: Tohoku J Exp Med
  doi: 10.1620/tjem.193.197
– volume: 9
  start-page: 1679
  issue: 8
  year: 2013
  ident: ref11
  article-title: Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/hv.24844
– volume: 42
  start-page: 609
  issue: 3
  year: 2011
  ident: ref13
  article-title: Hepatitis B and hepatitis C virus in Thai blood donors
  publication-title: Southeast Asian J Trop Med Public Health
– volume: 9
  start-page: 1679
  issue: 8
  year: 2013
  ident: ref24
  article-title: Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/hv.24844
– volume: 2
  start-page: ofv122
  issue: 4
  year: 2015
  ident: ref6
  article-title: A Survey Study of Pregnant Women and Healthcare Practitioners Assessing the Knowledge of Attitudes and Practices of Hepatitis B Management at a Teaching Hospital in Kumasi, Ghana, West Africa
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofv122
– volume: 2
  start-page: 50
  issue: 1
  year: 2005
  ident: ref2
  article-title: Epidemiology and Prevention of Hepatitis B Virus Infection
  publication-title: Int J Med Sci
  doi: 10.7150/ijms.2.50
– volume: 18
  start-page: 369
  issue: 5
  year: 2011
  ident: ref22
  article-title: Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
  publication-title: J Viral Hepat
  doi: 10.1111/j.1365-2893.2010.01312.x
– volume: 29
  start-page: 954
  issue: 3
  year: 1999
  ident: ref19
  article-title: Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen
  publication-title: Hepatology
  doi: 10.1002/hep.510290349
– volume: 8
  start-page: 896
  issue: 7
  year: 2012
  ident: ref23
  article-title: Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/hv.19989
– reference: 10921376 - J Gastroenterol Hepatol. 2000 May;15 Suppl:E16-9
– reference: 10051503 - Hepatology. 1999 Mar;29(3):954-9
– reference: 17002723 - Trop Med Int Health. 2006 Oct;11(10):1496-502
– reference: 26566533 - Open Forum Infect Dis. 2015 Sep 01;2(4):ofv122
– reference: 12450693 - Vaccine. 2002 Dec 13;21(3-4):188-93
– reference: 19473096 - J Infect Dis. 2009 Jul 1;200(1):33-8
– reference: 23485519 - J Hepatol. 2013 Jul;59(1):24-30
– reference: 11115720 - Vaccine. 2000 Nov 22;19(7-8):943-9
– reference: 10683538 - Vaccine. 2000 Feb 18;18 Suppl 1:S20-2
– reference: 11315767 - Tohoku J Exp Med. 2001 Mar;193(3):197-205
– reference: 22777097 - Hum Vaccin Immunother. 2012 Jul;8(7):896-904
– reference: 16339069 - Clin Diagn Lab Immunol. 2005 Dec;12(12):1442-7
– reference: 24843060 - Pediatrics. 2014 Jun;133(6):e1500-7
– reference: 7795104 - Clin Infect Dis. 1995 Apr;20(4):992-1000
– reference: 15968340 - Int J Med Sci. 2005;2(1):50-57
– reference: 20384962 - J Viral Hepat. 2011 May;18(5):369-75
– reference: 22711345 - J Med Virol. 2012 Aug;84(8):1177-85
– reference: 20116181 - Pathol Biol (Paris). 2010 Aug;58(4):296-300
– reference: 19716459 - Vaccine. 2009 Oct 19;27(44):6110-5
– reference: 25549238 - PLoS Med. 2014 Dec;11(12):e1001774
– reference: 23732904 - Hum Vaccin Immunother. 2013 Aug;9(8):1679-84
– reference: 10683019 - Lancet. 2000 Feb 12;355(9203):561-5
– reference: 26331587 - J Med Virol. 2016 Apr;88(4):664-73
– reference: 21706939 - Southeast Asian J Trop Med Public Health. 2011 May;42(3):609-15
– reference: 19892043 - Vaccine. 2010 Jan 8;28(3):730-6
SSID ssj0053866
Score 2.4804614
Snippet Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand's Expanded Program on Immunization (EPI), and extended to the...
Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand’s Expanded Program on Immunization (EPI), and extended to the...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e0150499
SubjectTerms Adolescent
Adolescents
Adult
Adults
Age
Antigens
Babies
Biology and Life Sciences
Child
Child, Preschool
Children
Drug dosages
Epidemiology
Eradication
Hepatitis
Hepatitis B
Hepatitis B - epidemiology
Hepatitis B - immunology
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B surface antigen
Hepatitis B vaccines
Hepatitis B Vaccines - therapeutic use
Hepatitis B virus - immunology
Hepatitis B virus - pathogenicity
Hepatocellular carcinoma
Hospitals
Humans
Immunization
Immunogenicity
Infant
Infections
Liver
Liver cancer
Liver diseases
Medicine
Medicine and Health Sciences
Middle Aged
Mothers
Neonates
Newborn babies
Pediatrics
People and Places
Population decline
Provinces
Thailand
Vaccination
Vaccines
Virology
Viruses
Young adults
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9QwDI_QPfGCGF87GBAQ0sFDt7ZJk_ZxQ5vukIAT29B4qtIm2U4a7Yn2_n_sJFdWNGk88Fo7VWM7tqPaPxPyTmqVM8tZZHVVRThsO1Ks4pHMYy1jbmxSYXPy5y9ifs4_XWQXN0Z9YU2Yhwf2gjuAFLngOGInrwS3olBK1LGxNovr2MIFAr0vxLztZcr7YDjFQoRGOSaTg6CX_XXbmH2843OH9fonEDm8_sErT9bXbXdbyvl35eSNUHTykDwIOSQ99N--Q-6Z5hHZCae0o-8DlPSHx6QHK6CnGzcUkbaWKhoKMWD53GAxdb_q6BFduC4R35FJl75ki6qOLkE-uO7sSq2wBHLW0ePlgrrB4jRN6Q84J92MOojhn6GLqXlCzk-Ozz7OozBnIarhttBHmdIMQrlO40wJ_M-Ya8g7cps48PY6r6RJRAFuU2O_dZ1KmWXMJHmhUyElY-wpmTQg2V1C61ibHDZVIRAdy2pVWauMgIeF1NbwKWFboZd1ACHHWRjXpfuzJuEy4mVYoqrKoKopiYZVaw_CcQf_Eepz4EUIbfcADKsMhlXeZVhT8hqtofT9qIMjKA8hnGNaVMBm3joOhNFosE7nUm26rlx8_f4PTKffRkyzwGRbEEetQm8E7AnhuUaceyNOcAb1iLyLtruVSlcmUoJqRSoTWLm159vJbwYyvhRr7xrTbjxPDoGAA88zb_6DZFNRMKCBsOToYIxEP6Y0qyuHYs4lgi_K5_9DVy_IfUhkhasNZHtk0v_amJeQLPbVK-cXfgN-xmcg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Public Health Database
  dbid: 8C1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZgkRCXipafLi1gEBJwSJvEiZ2cUFu12kUqrGiLyily_NOuVJJtsytx5DV4PZ6EGcebElQBV3scxTOe8die-YaQV0LLjNmEBVaXZYDFtgPJyiQQWahFmBgblZicfPiBj06S96fpqb9wa3xY5dImOkOta4V35NuRELDd8FhE72aXAVaNwtdVX0LjNrkTgQ1G7PxsrwvxAF3m3KfLMRFte-lszerKbOFJP3GIr9fbkUPt72zzYHZRNzc5nn_GT_62IR3cJyvek6Q7rehXyS1TrZG7h_6tfI2serVt6BuPLf32AfkGy4IeLVyVRFpbKqmPzIAvjQxGV8-nDd2lY5c20qZo0kkbw0VlQyew0nDc8bmcYkzkz-8_Gro_GVNXa5zGMf0CqtNAM3W4w199alP1kJwc7B_vjQJffCFQcISYB6nUDBiu4zCVHB8fMw3OSGYjh-iuslKYiOdgSzUmYatYiDRlJspyHXMhGGOPyKACRq8TqkJtMphYieh0LFWytFYaDo250NYkQ8KWMiiURybHAhkXhXtuE3BCaVlaoOQKL7khCbpRsxaZ4x_0uyjejhZxtV1DfXVWeDUt4ECWJ1jQKSt5YnkuJVehsTYNVWjhuDokz3FxFG2Samcdih3Y49FXymEyLx0FYmtUGLxzJhdNU4w_fv4PoqNPPaLXnsjWwA4lfcIEzAkxu3qUmz1KsBCq172OS3nJlaa41iUYuVzeN3e_6LrxoxiQV5l60dJksDskQPO41YaOszHPGfQBs0RPT3qs7_dU03MHbZ4IRGQUT_7-WxvkHvit3IUCsk0ymF8tzFPwDeflM2cAfgGiz2TE
  priority: 102
  providerName: ProQuest
Title The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation
URI https://www.ncbi.nlm.nih.gov/pubmed/26938736
https://www.proquest.com/docview/1770226271
https://www.proquest.com/docview/1770873041
https://pubmed.ncbi.nlm.nih.gov/PMC4777547
https://doaj.org/article/23094d8cd8b64f69aa6c0eff50c0f026
http://dx.doi.org/10.1371/journal.pone.0150499
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe27oUXxPhaxygGIRUeMiVxYicPCK1TS4u0UW0rKk-Rk9hbpZKWppXgv-fOcSOCithLHuJzKp_vfHf13e8IeStyGTEdMEfnaepgs21HsjRwROTmwg2U9lIsTr645MNJ8HkaTvfItmerZWC5M7TDflKT1fz0549fH0HhP5iuDcLbTjpdLgp1ihE8ePH75ABsk8BmDhdBfa8A2m1uL9FrcbjvMltM96-vNIyVwfSvT-7Wcr4od7mlf2dX_mGuBo_IQ-tn0rNKMA7Jnioek0OrySV9Z-Gm3z8ha5AUer0xjRPpQlNJbbIGTB8qTLhez0raoyNTSVJVbdJxldZFZUnHIHw47-ZOzjBNslvS_nhETfNx6vv0G-hS2aUGhvi7rXQqnpLJoH9zPnRsLwYng4hi7YQyZ2Duc98NJce7yCgH3yTSngF4z6JUKI_HcLTmWJOd-UKEIVNeFOc-F4Ix9oy0CuDsEaGZm6sIFpUiWB0LM5lqLRWHl7HItQrahG2ZnmQWqBz7ZcwTc_smIGCpeJjgViV2q9rEqWctK6CO_9D3cD9rWoTZNi8Wq9vEam0C8VkcYH-nKOWB5rGUPHOV1qGbuRqi1zZ5hdKQVDWr9WGRnIHJR9cphsW8MRQItVFgLs-t3JRlMvry9R5E11cNoq4l0gtgRyZt_QSsCSG8GpQnDUo4MLLG8BHK7pYrZeIJAVvLfeHBzK087x5-XQ_jRzE_r1CLTUUTgbEIgOZ5Jf41Z30eMxgDZomGYjRY3xwpZncG6TwQCNAoju_xuy_IA_BluUkPZCektV5t1EvwF9dph-yLqYBndO7hc_CpQw56_cvxVcf8A9MxR8RvzYVtBw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELaqIgEXRMtPFwo1CAQc0iZxYmcPCLWl1S7tlhXdVuUUnMRuVyrJ0uwKuPEavAQPxZMw4zgpQRVw6TUeW_HMeDy2Z74h5InIZMR0wBydJYmDxbYdyZLAEZGbCTdQ2kswOXmwx3sHwZuj8GiO_KhzYTCssraJxlBnRYp35GueELDdcF94ryafHKwaha-rdQmNSi121NfPcGQrX_Zfg3yf-v721miz59iqAk4KvvHUCWXGYKTMd0PJ8VUtymCXjbRnoMrTKBHK43AS5xlmF6e-EGHIlBd1M58LwfACFEz-lYAxgVj90WYTUgK2g3ObnseEt2a1YXVS5GoVbxYCgzB7vv2ZKgHNXjA_OS3KixzdP-M1f9sAt2-SG9ZzpeuVqi2QOZUvkqsD-za_SBasmSjpc4tl_eIW-QJqSPdnpiojLTSV1EaCwEg9hdHc03FJN2jfpKlUKaF0WMWMUVnSIWg29hudyDHGYP789r2kW8M-NbXNqe_T9yCTEj5Tg3P80aZS5bfJwaWI5Q6Zz4HRS4SmbqYimFiCaHgsTGWitVQcPnZFplXQIayWQZxaJHQsyHEam-c9ASeiiqUxSi62kusQp-k1qZBA_kG_geJtaBHH23wozo5jaxZiOAB2AywgFSU80LwrJU9dpXXopq6G43GHrKByxFVSbGON4nXwKdA368JkHhsKxPLIMVjoWM7KMu6_PfwPov13LaJnlkgXwI5U2gQNmBNihLUol1uUYJHSVvMSqnLNlTI-X7vQs1bvi5sfNc04KAYA5qqYVTQR7EYB0NytVkPDWZ93GbQBs0RrnbRY327JxycGSj0QiAAp7v39t1bItd5osBvv9vd27pPr4DNzE4bIlsn89GymHoBfOk0eGmNAyYfLtj6_ANP-nX4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0KoWqeKCaHl0oVCDQMAhbRIndnJAqKVd7VJaVrRFyyk4id2uVJKl2RVw4zf4FT6HL2HG8aYEVcCl13hsxTPjedjzIOSRyGXEdMAcnaepg822HcnSwBGRmws3UNpLMTl5b5_3j4JXo3C0QH7Mc2EwrHIuE42gzssM78g3PCFA3XBfeBvahkUMt3svJp8c7CCFL63zdho1i-yqr5_BfaueD7aB1o99v7dz-LLv2A4DTgZ28tQJZc5g1dx3Q8nxhS3KQeNG2jNly7MoFcrj4JXzHDONM1-IMGTKi-Lc50IwvAwF8X9FMFCbcJbEqHH2QI5wblP1GPyz5Yz1SVmodbxlCEy12XNVaDoGNHqhMzktq4uM3j9jN39Thr3r5Jq1YulmzXZLZEEVy2Rxz77TL5MlKzIq-tTWtX52g3wBlqQHM9OhkZaaSmqjQmClvsLI7um4olt0YFJW6vRQOqzjx6is6BC4HOcdnsgxxmP-_Pa9ojvDATV9zqnv0_dAkwo-U1Pz-KNNqypukqNLIcst0ikA0SuEZm6uIthYipXxWJjJVGupOHyMRa5V0CVsToMks1XRsTnHaWKe-gR4RzVKE6RcYinXJU4za1JXBfkH_BaSt4HFmt7mQ3l2nFgRkYAzGAfYTCpKeaB5LCXPXKV16GauBle5S9aQOZI6QbaRTMkm2Bdop8WwmYcGAut6FHhCjuWsqpLBm3f_AXTwtgX0xALpEtCRSZusAXvCemEtyNUWJEinrDW8gqw8x0qVnJ9jmDln74uHHzTDuCgGAxaqnNUwEWimAGBu16ehwazPYwZjgCzROict1LdHivGJKaseCKwGKe78_bfWyCLIneT1YH_3LrkK5jM3EYlslXSmZzN1D0zUaXrfyAJKPly28PkFybSh4A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Success+of+a+Universal+Hepatitis+B+Immunization+Program+as+Part+of+Thailand%27s+EPI+after+22+Years%27+Implementation&rft.jtitle=PloS+one&rft.au=Posuwan%2C+Nawarat&rft.au=Wanlapakorn%2C+Nasamon&rft.au=Sa-Nguanmoo%2C+Pattaratida&rft.au=Wasitthankasem%2C+Rujipat&rft.date=2016-03-03&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=11&rft.issue=3&rft.spage=e0150499&rft_id=info:doi/10.1371%2Fjournal.pone.0150499&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon